Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered in >30 countries. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is also utilised in the following products - the VivaGel® condom and VivaGel® BV. VivaGel® products have been licensed in >160 countries and are registered in >45 countries, including in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.
As a leading company in dendrimer-based drug delivery, Starpharma’s proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with MSD in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Partnered DEP® programs have the potential to generate significant future milestones and royalties.
Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX:SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.